Editas Medicine Stock Outperforms Medical Sector Amid Earnings Growth

Editas Medicine (EDIT) is a stock in the Medical sector that has outperformed its peers this year, with a 21.3% gain compared to a 4.2% average decline for the sector. The stock has a Zacks Rank of #2 (Buy) and a Zacks Consensus Estimate for full-year earnings that has increased 7.8% in the past quarter. Another Medical stock, Arbutus Biopharma (ABUS), has also outperformed the sector with a 2.5% year-to-date return and a Zacks Rank of #2 (Buy).

Editas Medicine (EDIT) and Arbutus Biopharma (ABUS) have both demonstrated strong performance in the first quarter of 2025, outperforming their respective sectors. Editas Medicine, a genome editing company, reported a quarterly loss of $0.43 per share, which was a significant improvement over the Zacks Consensus Estimate of $0.51 per share. This represents a 15.69% earnings surprise, marking the second time in the last four quarters that Editas has surpassed consensus EPS estimates [1].

The company's revenue for the quarter ended March 2025 was $4.66 million, a substantial increase of 385.21% compared to the Zacks Consensus Estimate. This compares to year-ago revenues of $1.14 million. Editas has shown resilience in the face of market challenges, with a 14.2% gain since the beginning of the year compared to the S&P 500's decline of -3.8% [1].

Arbutus Biopharma, a biopharmaceutical company focused on infectious diseases, reported a 2.5% year-to-date return, outperforming the sector. The company has a Zacks Rank of #2 (Buy), indicating positive future performance expectations. Arbutus has a robust pipeline, including AB-729, a subcutaneously-delivered RNA interference product candidate, and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication [2].

Both companies have shown strong performance and positive outlook, with Editas Medicine's Zacks Consensus Estimate for full-year earnings increasing by 7.8% in the past quarter. Investors should keep a close eye on the earnings outlook and management commentary for both companies to gauge future performance [1].

References:
[1] https://www.nasdaq.com/articles/editas-medicine-edit-reports-q1-loss-tops-revenue-estimates-1
[2] https://quantisnow.com/company/ABUS